Novartis Ilaris and others get CHMP nod for extensions
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP) has given the green light to several label extensions in its January meeting. Novartis' Ilaris got the go-ahead for gouty arthritis patients whose condition is not managed with current treatments, while Roche's hepatitis C drug Pegasys (peginterferon alfa-2a) was okayed for use in children.